Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern

Journal of Medical Virology

Volumn 82, Issue 11, 2010, Pages 1850-1858

  Damerow, Hans ^a   Yuen, Lilly ^b   Wiegand, Johannes ^a   Walker, Christine ^c   Bock, C Thomas ^c,d   Locarnini, Stephen ^b   Tillmann, Hans L ^a,e  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d ROBERT KOCH INSTITUTE   (Germany)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Genotype; HBV; Hepatitis B; Lamivudine; Resistance; YMDD

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE;

ANTIVIRAL RESISTANCE; AUSTRALIA; CLASSIFICATION; DRUG EFFECT; GENETICS; GENOTYPE; GERMANY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MUTATION; NUCLEOTIDE SEQUENCE; REVIEW; VIROLOGY;

ANTIVIRAL AGENTS; AUSTRALIA; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; GENOTYPE; GERMANY; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION;

EID: 77958189562     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21902     Document Type: Article

References (40)

1. Bottecchia M, Souto FJ, O KM, Amendola M, Brandao CE, Niel C, Gomes SA. 2008. Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: Characterization of genotype G in Brazil. BMC Microbiol 8: 11.
2. Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, Aslan N, Sezgin O, Sahin T, Bozdayi G, Cinar K, Pai SB, Pai R, Bozkaya H, Karayalçin S, Yurdaydin C, Schinazi RF. 2003. YSDD: A novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 10: 256-265.
3. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. 2009. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 51: 640-646.
4. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP. 2007. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: The German guidelines for the management of HBV infection. Z Gastroenterol 45: 1281-1328.
5. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77: 11833-11841.
6. Deterding K, Constantinescu I, Nedelcu FD, Gervain J, Nemecek V, Srtunecky O, Vince A, Grgurevic I, Bielawski KP, Zalewska M, Bock T, Ambrozaitis A, Stanczak J, Takács M, Chulanov V, Slusarczyk J, Drazd'áková M, Wiegand J, Cornberg M, Manns MP, Wedemeyer H. 2008. Prevalence of HBV genotypes in Central and Eastern Europe. J Med Virol 80: 1707-1711.
7. Economou M, Manolakopoulos S, Trikalinos TA, Filis S, Bethanis S, Tzourmakliotis D, Avgerinos A, Raptis S, Tsianos EV. 2005. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 11: 5882-5887.
8. Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S. 2007. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences. J Med Virol 79: 1664-1670.
9. Gora-Gebka M, Liberek A, Charmuszko U, Sikorska-Wisniewska G, Szlagatys-Sidorkiewicz A, Korzon M, Bielawski K. 2007. HBV gene variants and polymerse gene mutations in children with chronic hepatitis B in the course of the antiviral therapy. Med Wieku Rozwoj 11: 367-371.
10. Gwak GY, Huh W, Lee DH, Choi MS, Lee JH, Koh KC, Kim SJ, Joh JW, Oh HY. 2007. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc 39: 3121-3126.
11. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, Kim HT, Rim KS, Kang MS, Yoo W, Kim SO. 2004. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 40: 837-844.
12. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J. 2008. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 47: 447-454.
13. Iacomi F, Vincenti D, Vairo F, Solmone M, Mariano A, Piselli P, Puro V, Capobianchi MR, Antonucci G. 2009. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 81: 1151-1156.
14. Joh JW, Lee HH, Park JW, Lee DH, Yoo BC, Lee KW, Kim SJ. 2005. Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients. Transplant Proc 37: 1235-1237.
15. Kim KH, Lee KH, Chang HY, Ahn SH, Tong S, Yoon YJ, Seong BL, Kim SI, Han KH. 2003. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol 71: 367-375.
16. Kim H, Jee YM, Song BC, Shin JW, Yang SH, Mun HS, Kim HJ, Oh EJ, Yoon JH, Kim YJ, Lee HS, Hwang ES, Cha CY, Kook YH, Kim BJ. 2007. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 50: 52-57.
17. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, Globe Study Group. 2007. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357: 2576-2588.
18. Lee SY, Choi MS, Lee D, Lee JH, Koh KC, Paik SW, Yoo BC. 2005. Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy. J Korean Med Sci 20: 433-437.
19. Lee CH, Kim SO, Byun KS, Moon MS, Kim EO, Yeon JE, Yoo W, Hong SP. 2006. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 130: 1144-1152.
20. Li MW, Hou W, Wo JE, Liu KZ. 2005. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. J Zhejiang Univ Sci B 6: 664-667.
21. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, GLOBE Study Group. 2009. 2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136: 486-495.
22. Lok AS, McMahon BJ. 2004. Chronic hepatitis B: Update of recommendations. Hepatology 39: 857-861.
23. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. 2004. Genetic diversity of hepatitis B virus strains derived worldwide: Genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47: 289-309.
24. Pai SB, Bozdayi AM, Pai RB, Beker T, Sarioglu M, Turkyilmaz AR, Grier J, Yurdaydin C, Schinazi RF. 2005. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother 49: 2618-2624.
25. Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM. 2006. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir Ther 11: 447-455.
26. Papatheodoridis GV, Deutsch M. 2008. Resistance issues in treating chronic hepatitis B. Future Microbiol 3: 525-538.
27. Song LH, Binh VQ, Duy DN, Juliger S, Bock TC, Luty AJ, Kremsner PG, Kun JF. 2003. Mannose-binding lectin gene polymorphisms and hepatitis B virus infection in Vietnamese patients. Mutat Res 522: 119-125.
28. Suzuki F, Suzuki Y, Akuta N, Yatsuji H, Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, Kobayashi M, Watahiki S, Kumada H. 2008. Changes in viral loads of lamivudine-resistant mutants during entecavir therapy. Hepatol Res 38: 132-140.
29. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48: 3498-3507.
30. Tillmann HL. 2007. Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. Curr Opin Investig Drugs 8: 682-690.
31. Tillmann HL. 2008. The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Ther Clin Risk Manag 4: 797-802.
32. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M, Oldhafer K, Bruns I, Gauthier J, Condreay LD, Raab HR, Manns MP. 1999. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 30: 244-256.
33. Toan NL, Song le H, Kremsner PG, Duy DN, Binh VQ, Koeberlein B, Kaiser S, Kandolf R, Torresi J, Bock CT. 2006. Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology 43: 1375-1384.
34. Walsh AW, Langley DR, Colonno RJ, Tenney DJ. 2010. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS ONE 5: e9195.
35. Warner N, Locarnini S. 2008. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48: 88-98.
36. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T. 2007. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 51: 2285-2292.
37. Wiegand J, Hasenclever D, Tillmann HL. 2008. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 13: 211-220.
38. Woo HY, Park H, Kim BI, Jeon WK, Cho YK, Kim YJ. 2007. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients. Antivir Ther 12: 7-13.
39. Woo HY, Park H, Kim BI, Jeon WK, Kim YJ. 2008. Evaluation of dual priming oligonucleotide-based multiplex PCR for detection of HBV YMDD mutants. Arch Virol 153: 2019-2025.
40. Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, Locarnini SA, Bartholomeusz A. 2007. SeqHepB: A sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 75: 64-74.